Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Eur J Med Genet ; 63(4): 103783, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31605815

ABSTRACT

BACKGROUND: The specific distribution of cancers in Down syndrome (DS) calls into question the validity of screening policies for cancer surveillance as implemented for the general population. METHODS: We performed a literature review of cancer screening opportunities for adults with DS, taking account of the tumor profile in this specific population. RESULTS: In DS, solid tumors in adults are at most half as common as in the overall group of persons with intellectual disabilities, who have a frequency similar to that of the general population. In women with DS, breast cancer is rare, the frequency of colorectal cancer is poorly described, and cervical cancer is rarely reported, although sometimes observed at an advanced stage. Young men have an increased risk of testicular cancer. DISCUSSION: We propose that adults with DS should participate in colon cancer screening. For women with DS, breast cancer screening is not recommended, but annual clinical monitoring should be conducted, with the option to perform ultrasound or MRI examination in suspect cases. For cervical cancer, screening could be proposed to women who are sexually active beginning at age 25 years. Annual surveillance for testicular cancer via palpation by a health professional is preferable from ages 15 to 45. In case of additional genetic predisposition in a person with DS, a surveillance similar to other family members is recommended. CONCLUSION: The specific tumor profile in DS warrants an adapted screening program for breast, colon, cervical and testicular neoplasia.


Subject(s)
Down Syndrome/complications , Early Detection of Cancer/methods , Neoplasms/drug therapy , Adult , Humans , Neoplasms/etiology , Prognosis
2.
Am J Med Genet A ; 176(12): 2685-2694, 2018 12.
Article in English | MEDLINE | ID: mdl-30569664

ABSTRACT

We present new and complete growth charts for 2,598 healthy French children and adolescents with Down syndrome (DS) from 0 to 20 years old, obtained with highly reliable statistical methods. This study is retrospective and addresses data collected over a period of 12 years, monocentric and with a satisfactory representation of the population nationwide. Final occipito-frontal circumference (OFC) is at the fifth percentile compared to WHO charts, with a drop between 12 and 18 months. Final height is at the first percentile compared to WHO charts for girls and boys with two periods of reduced growth velocity: before 36 months and around puberty. We observed no pubertal growth peak for girls. For boys, pubertal growth peak showed to happen earlier and to be less significant than in the general population. When compared to a previous French study with people affected with DS, pubertal growth acceleration begins at a later age for girls and boys; girls in our study are taller at age 15 (+5 cm), but there is no difference for boys at this age. Overweight is more frequent compared to the typical French population. Mean body mass index (BMI) rises rapidly above the 75th percentile of typical French children as early as age 4, with an earlier age for precocious adiposity rebound. The second period for rapid increase of BMI is around 14 years old. When compared to a previous French study with DS, we did not observe any BMI increase, at least up to the age of 14.


Subject(s)
Down Syndrome/epidemiology , Growth Charts , Adiposity , Adolescent , Body Height , Body Mass Index , Body Weight , Child , Child, Preschool , Down Syndrome/history , Electronic Health Records , Female , History, 20th Century , History, 21st Century , Humans , Infant , Infant, Newborn , Male , Retrospective Studies , Young Adult
3.
Am J Med Genet A ; 173(8): 2166-2175, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28574650

ABSTRACT

The objectives of this study were to obtain updated neonatal measurements in French newborns with Down Syndrome (DS) according to their gestational age, and to assess the frequency and distribution of congenital anomalies. Data on congenital malformations, birth weight, birth length and birth occipito-frontal circumference (OFC) according to the gestational age was gathered from 1,030 babies, born between 1980 and 2010. The mean gestational age was 38 weeks from the date of the last menstrual period (LMP) (range: 29-42 weeks). Repartition of complications was found to be similar to previous studies, with no difference according to the date of birth. For girls born after 37 weeks, the mean birth weight was 3,012 ± 430 g, the mean birth length was 47.7 ± 2 cm, and the mean birth OFC was 33 ± 1.4 cm. For boys born after 37 weeks, the mean birth weight was 3,103 ± 459, the mean birth length was 48.4 ± 2.2 cm, and the mean birth OFC was 33.2 ± 1.4 cm. We did not find any difference in these measurements when we compared children born before 1997 and after 2007. When compared to the general population (French data and WHO charts), newborns with DS have a more pronounced difference in their birth length and their birth OFC (15-25th) than in their birth weight (25-50th). The shape of the growth curves shows that growth velocity decreases during the last weeks of gestation in all measurements, which suggests that the modal age for delivery could be earlier in DS newborns than in the general population.


Subject(s)
Anthropometry , Birth Weight , Congenital Abnormalities/physiopathology , Down Syndrome/physiopathology , Congenital Abnormalities/epidemiology , Delivery, Obstetric , Down Syndrome/epidemiology , Female , Gestational Age , Humans , Infant, Newborn , Male , Pregnancy
4.
Brain Sci ; 7(6)2017 May 27.
Article in English | MEDLINE | ID: mdl-28555009

ABSTRACT

Abstract: Adolescents and young adults with Down syndrome (DS) can present a rapid regression with loss of independence and daily skills. Causes of regression are unknown and treatment is most of the time symptomatic. We did a retrospective cohort study of regression cases: patients were born between 1959 and 2000, and were followed from 1984 to now. We found 30 DS patients aged 11 to 30 years old with history of regression. Regression occurred regardless of the cognitive level (severe, moderate, or mild intellectual disability (ID)). Patients presented psychiatric symptoms (catatonia, depression, delusions, stereotypies, etc.), partial or total loss of independence in activities of daily living (dressing, toilet, meals, and continence), language impairment (silence, whispered voice, etc.), and loss of academic skills. All patients experienced severe emotional stress prior to regression, which may be considered the trigger. Partial or total recovery was observed for about 50% of them. In our cohort, girls were more frequently affected than boys (64%). Neurobiological hypotheses are discussed as well as preventative and therapeutic approaches.

5.
Tumori ; 99(4): e169-71, 2013.
Article in English | MEDLINE | ID: mdl-24326855

ABSTRACT

Lung cancer is rare in persons with Down syndrome, and the clinical presentation of the disease has not been described in adults with intellectual disability. We report the first detailed clinical observation of a 33-year-old man with Down syndrome who developed an adenocarcinoma of the lung 30 years after an acute lymphoblastic leukemia in infancy. Despite advanced disease at initial presentation and extensive tumor spreading during the course of the disease, he presented with unusually mild symptoms. The scarcity of lung cancer in people with intellectual disability, and particularly those with Down syndrome, is due, in part, to reduced tobacco use. However, cytogenetic and molecular studies suggest that genes mapping to chromosome 21 may protect against lung cancer. Numerous reports also suggest that, in persons with Down syndrome and other intellectual disability, cancers are often discovered late, leading to loss of the chance of cure and recovery.


Subject(s)
Adenocarcinoma , Down Syndrome , Lung Neoplasms , Precursor Cell Lymphoblastic Leukemia-Lymphoma , Adenocarcinoma/diagnosis , Adenocarcinoma/drug therapy , Adenocarcinoma/genetics , Adenocarcinoma of Lung , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child, Preschool , Drug Resistance, Neoplasm , Erlotinib Hydrochloride , Fatal Outcome , Humans , Intellectual Disability/etiology , Lung Neoplasms/diagnosis , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Male , Palliative Care , Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Quinazolines/therapeutic use , Tomography, X-Ray Computed
6.
Eur J Hum Genet ; 21(11): 1253-9, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23422941

ABSTRACT

Trisomy 21 (T21), or Down syndrome (DS), is the most frequent and recognizable cause of intellectual disabilities. The level of disability, as evaluated by the intelligence quotient (IQ) test, varies considerably between patients independent of other factors. To determine the genetic or molecular basis of this difference, a high throughput transcriptomic analysis was performed on twenty T21 patients with high and low IQ, and 10 healthy controls using Digital Gene Expression. More than 90 millions of tags were sequenced in the three libraries. A total of 80 genes of potential interest were selected for the qPCR experiment validation, and three housekeeping genes were used for normalizing purposes. HLA DQA1 and HLA DRB1 were significantly downregulated among the patients with a low IQ, the values found in the healthy controls being intermediate between those noted in the IQ+ and IQ- T21 patients. Interestingly, the intergenic region between these genes contains a binding sequence for the CCCTC-binding factor, or CTCF, and cohesin (a multisubunit complex), both of which are essential for expression of HLA DQA1 and HLA DRB1 and numerous other genes. Our results might lead to the discovery of genes, or genetic markers, that are directly involved in several phenotypes of DS and, eventually, to the identification of potential targets for therapeutic interventions.


Subject(s)
Down Syndrome/genetics , Gene Expression Regulation , Intellectual Disability/genetics , Intelligence Tests , Adolescent , Adult , Case-Control Studies , Down Syndrome/blood , Female , Gene Expression Profiling , HLA-DQ alpha-Chains/genetics , HLA-DRB1 Chains/genetics , Humans , Intellectual Disability/blood , Male , RNA, Messenger/genetics , RNA, Messenger/metabolism , Young Adult
7.
PLoS One ; 5(1): e8394, 2010 Jan 11.
Article in English | MEDLINE | ID: mdl-20084109

ABSTRACT

BACKGROUND: Seven genes involved in folate metabolism are located on chromosome 21. Previous studies have shown that folate deficiency may contribute to mental retardation in Down's syndrome (DS). METHODOLOGY: We investigated the effect of oral folate supplementation (daily dose of 1.0+/-0.3 mg/kg) on cognitive functions in DS children, aged from 3 to 30 months. They received 1 mg/kg leucovorin or placebo daily, for 12 months, in a single-centre, randomised, double-blind study. Folinic acid (leucovorin, LV) was preferred to folic acid as its bioavailability is higher. The developmental age (DA) of the patients was assessed on the Brunet-Lezine scale, from baseline to the end of treatment. RESULTS: The intent-to-treat analysis (113 patients) did not show a positive effect of leucovorin treatment. However, it identified important factors influencing treatment effect, such as age, sex, and concomitant treatments, including thyroid treatment in particular. A per protocol analysis was carried out on patients evaluated by the same examiner at the beginning and end of the treatment period. This analysis of 87 patients (43 LV-treated vs. 44 patients on placebo) revealed a positive effect of leucovorin on developmental age (DA). DA was 53.1% the normal value with leucovorin and only 44.1% with placebo (p<0.05). This positive effect of leucovorin was particularly strong in patients receiving concomitant thyroxin treatment (59.5% vs. 41.8%, p<0.05). No adverse event related to leucovorin was observed. CONCLUSION: These results suggest that leucovorin improves the psychomotor development of children with Down's syndrome, at least in some subgroups of the DS population, particularly those on thyroxin treatment. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00294593.


Subject(s)
Down Syndrome/psychology , Leucovorin/administration & dosage , Thyroid Gland/physiopathology , Child, Preschool , Double-Blind Method , Down Syndrome/physiopathology , Female , Humans , Infant , Male , Placebos
8.
Genet Med ; 11(9): 611-6, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19636252

ABSTRACT

Trisomy 21 or Down syndrome is a chromosomal disorder resulting from the presence of all or part of an extra Chromosome 21. It is a common birth defect, the most frequent and most recognizable form of mental retardation, appearing in about 1 of every 700 newborns. Although the syndrome had been described thousands of years before, it was named after John Langdon Down who reported its clinical description in 1866. The suspected association of Down syndrome with a chromosomal abnormality was confirmed by Lejeune et al. in 1959. Fifty years after the discovery of the origin of Down syndrome, the term "mongolism" is still inappropriately used; persons with Down syndrome are still institutionalized. Health problems associated with that syndrome often receive no or little medical care, and many patients still die prematurely in infancy or early adulthood. Nevertheless, working against this negative reality, community-based associations have lobbied for medical care and research to support persons with Down syndrome. Different Trisomy 21 research groups have already identified candidate genes that are potentially involved in the formation of specific Down syndrome features. These advances in turn may help to develop targeted medical treatments for persons with Trisomy 21. A review on those achievements is discussed.


Subject(s)
Chromosomes, Human, Pair 21/genetics , Down Syndrome/drug therapy , Down Syndrome/genetics , Trisomy/genetics , Animals , Clinical Trials as Topic , Disease Models, Animal , Down Syndrome/history , Gene Dosage , Genotype , History, 20th Century , History, 21st Century , Humans , Mice , Phenotype
9.
Br J Nutr ; 94(2): 166-9, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16115349

ABSTRACT

The cause of the non-disjunction leading to trisomy 21 remains unclear. Recent evidence has suggested that 5,10-methylenetetrahydrofolate reductase (MTHFR) and/or methionine synthase reductase (MTRR) might contribute to the maternal risk of trisomy 21. The purpose of the present study was to analyse these findings among the French population and to investigate whether common polymorphisms in genes of the folate and homocysteine pathway, including the MTHFR 677C > T, MTHFR 1298A > C, the methionine synthase (MTR) 2756A > G, the cystathionine beta-synthase (CBS) 844Ins68 and the reduced folate carrier (RFC-1) 80G > A polymorphisms, contribute to the risk of trisomy 21. The risk was studied by analysing independent and combined genotypes in 119 case mothers and 119 control mothers. The MTHFR 677T, MTHFR 1298C, MTR2756G, MTRR66G, CBSIns68+ and the RFC-1 80G allele frequencies were not significantly different among French case mothers, compared with control mothers. The risk of having a child with trisomy 21 did not appear to be linked to polymorphisms in genes associated with folate and homocysteine metabolism.


Subject(s)
Down Syndrome/genetics , Folic Acid/genetics , Homocysteine/genetics , Polymorphism, Genetic/genetics , 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase/genetics , Adult , Down Syndrome/metabolism , Female , Ferredoxin-NADP Reductase/genetics , Folic Acid/metabolism , France , Genotype , Homocysteine/metabolism , Humans , Membrane Transport Proteins/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Mothers , Reduced Folate Carrier Protein , Risk Factors
10.
Am J Clin Nutr ; 80(6): 1551-7, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15585767

ABSTRACT

BACKGROUND: The effects of supplementation with B vitamins and of common polymorphisms in genes involved in homocysteine metabolism on plasma total homocysteine (tHcy) concentrations in trisomy 21 are unknown. OBJECTIVES: We aimed to determine the effects of orally administered folic acid and of folic acid combined with vitamin B-12, vitamin B-6, or both on tHcy in adults with trisomy 21. The study was also intended to analyze the possible influence of gene polymorphisms. DESIGN: One hundred sixty adults with trisomy 21 and 160 healthy, unrelated subjects aged 26 +/- 4 y were included. Plasma tHcy, red blood cell folate, serum folate, and vitamin B-12 were measured. Genotyping for the common methylenetetrahydrofolate reductase (MTHFR) 677C-->T, MTHFR 1298A-->C, cystathionine beta-synthase 844Ins68, methionine synthase 2756A-->C, methionine synthase reductase 66A-->G, and reduced folate carrier 80G-->A polymorphisms was carried out. RESULTS: The mean tHcy concentration (9.8 +/- 0.7 micromol/L) of cases who did not use vitamins was not significantly different from that of controls (9.4 +/- 0.3 micromol/L). Plasma tHcy concentrations (7.6 +/- 0.3 mmol/L) in cases who used folic acid were significantly lower than in cases who did not. Folic acid combined with vitamin B-12 did not significantly change tHcy concentrations compared with those in cases who used only folic acid. Folic acid combined with vitamins B-6 and B-12 significantly lowered tHcy (6.5 +/- 0.5 micromol/L). The difference in tHcy according to MTHFR genotype was not significant. However, tHcy concentrations were slightly higher in TT homozygotes among the controls but not among the cases. CONCLUSION: This study provides information on the relation between several polymorphisms in genes involved in homocysteine and folate metabolism in adults with trisomy 21.


Subject(s)
Down Syndrome/blood , Folic Acid/administration & dosage , Homocysteine/blood , Polymorphism, Genetic , Vitamin B 12/administration & dosage , Vitamin B 6/administration & dosage , 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase/genetics , Administration, Oral , Adolescent , Adult , Case-Control Studies , Cystathionine beta-Synthase/genetics , Dietary Supplements , Down Syndrome/drug therapy , Down Syndrome/genetics , Drug Synergism , Female , Ferredoxin-NADP Reductase/genetics , Folic Acid/blood , Genotype , Homocysteine/drug effects , Homozygote , Humans , Male , Membrane Transport Proteins/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Middle Aged , Reduced Folate Carrier Protein , Vitamin B 12/blood
12.
Am J Med Genet A ; 118A(2): 176-9, 2003 Apr 15.
Article in English | MEDLINE | ID: mdl-12655498

ABSTRACT

A girl with a de novo interstitial deletion of the short arm of chromosome 1 (46,XX,del (1)(p22p32) is described with moderate developmental delay and minor phenotypic abnormality. These clinical manifestations are compared to previously reported patients with interstitial deletion of chromosome 1, in an attempt to identify a clinical phenotype which seems quite different from the syndrome linked to more terminal deletion of chromosome 1p, and perhaps from more proximal 1p deletion phenotype.


Subject(s)
Chromosome Deletion , Chromosomes, Human, Pair 1/genetics , Child, Preschool , Developmental Disabilities/genetics , Developmental Disabilities/pathology , Female , Humans , Karyotyping , Phenotype
SELECTION OF CITATIONS
SEARCH DETAIL
...